Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2012. The report details a specific share repurchase transaction executed on May 11, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Repurchased: 800,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,424 pence per share; lowest price paid was 1,405 pence per share.
- Treasury Holdings (Settled): 525,297,927 shares (9.44% of total issued share capital).
- Treasury Holdings (Including Unsettled): 528,947,927 shares (10.50% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,039,216,271 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the repurchase of 800,000 shares. Consequently, the percentage of shares held in Treasury increased to 10.50% of total voting rights when including unsettled purchases. The filing does not provide comparative data to prior periods regarding these specific metrics.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,039,216,271) for calculating disclosure thresholds under FSA rules.
- Confirm the current percentage of voting rights held in Treasury (10.50% including unsettled shares).
- Review the specific price range paid (1,405 to 1,424 pence) for the May 11, 2012 transaction.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.